Robert Perri, M.D.

VA Medical Center

Selected Publications

Perri RT, Kay NE.  Malignant chronic lymphocytic leukemia B cells express interleukin 2 receptors but fail to respond to interleukin 2’s proliferative signal.  Leukemia 1987; 1:127-130.

Weisdorf DJ, Perri RT, Arthur DC, Macnicki JL, Oken MM, Miller WJ.  In vitro correlates of low dose ara-C efficacy: Clinical, cytogenetic, and bone marrow culture analysis.  Am J Hematol 1987; 25:43-53.

Kay NE, Perri RT.  Natural killer function in B-chronic lymphocytic leukemia.  Nouv Rev Fr Hematol 1988; 30:343-345.

Kay NE, Perri RT.  Immunobiology of malignant B cells and immunoregulatory cells in B-chronic lymphocytic leukemia.  Clin Lab Med 1988; 8:163-177.

Kay NE, Perri RT.  Evidence that large granular lymphocytes from B-CLL patients with hypogammaglobulinemia down-regulate B-cell immunoglobulin synthesis.  Blood 1989; 73:1016-1019.

Perri RT, Kay NE.  Large granular lymphocytes from B-chronic lymphocytic leukemia patients inhibit normal B cell proliferation.  Am J Hematol 1989; 31:166-172.

Niehans GA, Jaszcz W, Brunetto V, Perri RT, Gajl-Peczalska K, Wick MR, Tsuruo T, Bloomfeld CD.  Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas.  Cancer Res 1992; 52:3768-3775.

Omura GA, Perri RT, Peterson B, Schiffer CA.  Carboplatin in previously treated multiple myeloma.  A Cancer and Leukemia Group B phase II trial.  Am J Clin Oncol 1994; 17:196-198.

Lichtman SM, Petroni G, Schilsky RL, Johnson JL, Perri RT, Niedzwiecki D, Sklar J, Barcos M, Peterson BA. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Leuk Lymphoma 2001; 42:1255-64.